These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19523545)

  • 1. A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells.
    Stessl M; Marchetti-Deschmann M; Winkler J; Lachmann B; Allmaier G; Noe CR
    J Proteomics; 2009 Aug; 72(6):1019-30. PubMed ID: 19523545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-target effects related to the phosphorothioate modification of nucleic acids.
    Winkler J; Stessl M; Amartey J; Noe CR
    ChemMedChem; 2010 Aug; 5(8):1344-52. PubMed ID: 20544786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor efficacy of oblimersen Bcl-2 antisense oligonucleotide alone and in combination with vinorelbine in xenograft models of human non-small cell lung cancer.
    Hu Y; Bebb G; Tan S; Ng R; Yan H; Sartor JR; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Nov; 10(22):7662-70. PubMed ID: 15569999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
    Herbst RS; Frankel SR
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ; Gillum AM; Klem RE; Frankel SR
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature.
    Anderson EM; Miller P; Ilsley D; Marshall W; Khvorova A; Stein CA; Benimetskaya L
    Cancer Gene Ther; 2006 Apr; 13(4):406-14. PubMed ID: 16195754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.
    Benimetskaya L; Lai JC; Khvorova A; Wu S; Hua E; Miller P; Zhang LM; Stein CA
    Clin Cancer Res; 2004 Dec; 10(24):8371-9. PubMed ID: 15623615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oblimersen in the treatment of metastatic melanoma.
    Tarhini AA; Kirkwood JM
    Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines.
    Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T
    Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro.
    Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA
    Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen).
    Raffo A; Lai JC; Stein CA; Miller P; Scaringe S; Khvorova A; Benimetskaya L
    Clin Cancer Res; 2004 May; 10(9):3195-206. PubMed ID: 15131061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.
    Moreira JN; Santos A; Simões S
    Rev Recent Clin Trials; 2006 Sep; 1(3):217-35. PubMed ID: 18473975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of apoptosis by G3139 in melanoma cells.
    Benimetskaya L; Lai JC; Khvorova A; Wu S; Miller P; Stein CA
    Ann N Y Acad Sci; 2005 Nov; 1058():235-45. PubMed ID: 16394140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bcl-2 antisense therapy in multiple myeloma.
    Chanan-Khan AA
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):21-4. PubMed ID: 15651173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorothioate oligonucleotides block the VDAC channel.
    Tan W; Loke YH; Stein CA; Miller P; Colombini M
    Biophys J; 2007 Aug; 93(4):1184-91. PubMed ID: 17483171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
    J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential therapeutic applications of oblimersen in CLL.
    Koziner B
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):32-8. PubMed ID: 15651175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.